Menu Search
Equities

Aurinia Pharmaceuticals Inc

AUPH:NMQ

Aurinia Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)8.86
  • Today's Change0.09 / 1.03%
  • Shares traded1.60m
  • 1 Year change-1.99%
  • Beta1.4035
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Aurinia Pharmaceuticals Inc grew revenues 30.95% from 134.03m to 175.51m while net income improved from a loss of 108.18m to a smaller loss of 78.02m.
Gross margin87.25%
Net profit margin-10.23%
Operating margin-14.84%
Return on assets-4.08%
Return on equity-5.78%
Return on investment-4.74%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Aurinia Pharmaceuticals Inc fell by 45.30m. Cash Flow from Financing was negative, which signals that this company did not need to attract significant financing from outside sources. In addition the company used 33.46m for operations while cash used for investing totalled 6.71m.
Cash flow per share-0.0209
Price/Cash flow per share--
Book value per share2.71
Tangible book value per share2.68
More ▼

Balance sheet in USDView more

Aurinia Pharmaceuticals Inc has a Debt to Total Capital ratio of 17.25%, a lower figure than the previous year's 18.42%.
Current ratio5.60
Quick ratio5.11
Total debt/total equity0.2085
Total debt/total capital0.1725
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.